Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study

Open access
Jones, Stacie M, Kim, Edwin H, Nadeau, Kari C, Nowak-Wegrzyn, Anna, Wood, Robert A, Sampson, Hugh A, Scurlock, Amy M, Chinthrajah, Sharon, Wang, Julie, Pesek, Robert D, Sindher, Sayantani B, Kulis, Mike, Johnson, Jacqueline, Spain, Katharine, Babineau, Denise C, Chin, Hyunsook, Laurienzo-Panza, Joy, Yan, Rachel, Larson, David, Qin, Tielin, Whitehouse, Don, Sever, Michelle L, Sanda, Srinath, Plaut, Marshall, Wheatley, Lisa M, Burks, A Wesley · 2022 · The Lancet

Abstract

SUMMARY Background. For young, peanut-allergic children, dietary avoidance is the current standard of care. We evaluated whether peanut oral immunotherapy (PnOIT) can induce desensitization (an increased allergic reaction threshold while on therapy) and/or remission (a state of nonresponsiveness following discontinuation of immunotherapy) in this population. Methods. A randomized, double-blind, placebo-controlled study was conducted in 5 US centers among children (ages 12–<48 months), reactive to ≤500 mg peanut protein during double-blind, placebo-controlled food challenge (DBPCFC). Participants were computer-randomized using a 2:1 allocation ratio to receive PnOIT or placebo for 134 weeks (2000 mg peanut protein/day) followed by 26 weeks of avoidance with participants and study staff/investigators blinded to treatment arm assignment. Desensitization at the end of treatment (week 134), as the primary outcome, and remission after avoidance (week 160), as the key secondary outcome, were assessed by DBPCFC to 5000 mg. Safety and immunological parameters were assessed. Findings. Of 146 children, with a median age of 39.3 (IQR:30.8,44.7) months, randomized from August 2013 to October 2015, 96 were assigned and analyzed in the PnOIT-treatment arm and 50 in the placebo-treatment arm. At week 134, 68/96 (71%; 95% CI:61%,80%) PnOIT-treated compared to 1/50 (2%; 95% CI:0.05%,11%) placebo-treated participants met the primary outcome of desensitization (risk difference (RD)=69%; 95% CI:59%,79%; p<0.0001). The median cumulative tolerated dose (CTD) during the week 134 DBPCFC was 5005 mg (Interquartile Range (IQR):3755,5005) for PnOIT-treated versus 5 mg (IQR:0,105) for placebo-treated (p<0.0001). After avoidance, 20/96 (21%; 95% CI:13%,30%) on PnOIT compared to 1/50 (2%; 95% CI:0.05%,11%) on placebo met remission criteria (RD:19%; 95% CI:10%,28%; p=0.0021). The median CTD during the week 160 DBPCFC was 755 mg (IQR:0,2755) for the PnOIT-treated and 0 mg (IQR:0,55) for placebo-treated (p<0.0001). A significant proportion of PnOIT participants who passed the 5000 mg DBPCFC at week 134 could no longer tolerate 5000 mg at week 160 (p<0.001). The placebo participant who was desensitized at week 134 also achieved remission at week 160. Compared to placebo treatment, peanut- and Ara h2-specific-IgE, skin prick test, and basophil activation decreased, while peanut- and Ara h2-specific-IgG4 increased in PnOIT-treated participants at weeks 134 and 160. Using multivariable regression analysis of PnOIT-treated participants, younger age and lower baseline peanut-specific IgE was predictive of remission. Most participants (98% PnOIT vs. 80% placebo) experienced at least 1 OIT dosing reaction, predominantly mild-moderate and occurring more frequently in PnOIT-treated participants; 35 OIT dosing events with moderate symptoms were treated with epinephrine in 21 PnOIT participants. Interpretation. In peanut-allergic children, initiation of PnOIT before age 4 years is associated with an increase in both desensitization and remission. Development of remission correlates with immunologic biomarkers. The outcomes suggest a window of opportunity at a young age for intervention to induce remission. Funding. National Institute of Allergy and Infectious Disease, Immune Tolerance Network Trial registration: The trial is registered on clinicaltrials.gov (NCT03345160).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02390-4

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 345

Metadata

Authors
Jones, S. M., Kim, E. H., Nadeau, K. C., Nowak-Wegrzyn, A., Wood, R. A., Sampson, H. A., Scurlock, A. M., Chinthrajah, S., Wang, J., Pesek, R. D., Sindher, S. B., Kulis, M., Johnson, J., Spain, K., Babineau, D. C., Chin, H., Laurienzo-Panza, J., Yan, R., Larson, D., Qin, T., Whitehouse, D., Sever, M. L., Sanda, S., Plaut, M., Wheatley, L. M., & Burks, A. W.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-01
Volume
399
Issue
10322
Pages
359-371
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4206035800
Cited by
345
References
27
FWCI
40.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02390-4
The paper
Jones, S. M., Kim, E. H., Nadeau, K. C., Nowak-Wegrzyn, A., Wood, R. A., Sampson, H. A., Scurlock, A. M., Chinthrajah, S., Wang, J., Pesek, R. D., Sindher, S. B., Kulis, M., Johnson, J., Spain, K., Babineau, D. C., Chin, H., Laurienzo-Panza, J., Yan, R., Larson, D., . . . Burks, A. W. (2022). Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(21)02390-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.